You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Globalization of Internal R&D

Ironwood’s long-term goal is to get our medicines to appropriate patients around the world in the most efficient way possible. In some cases, this may be best achieved by accessing the infrastructure of collaborators with specific regional expertise. With our first internally-developed medicine, linaclotide, we’ve established the following network of partners to help us reach patients, and we may broaden this network in the future, either to support linaclotide or other programs.

NORTH AMERICA

LINZESS®* available in U.S. through 50/50 collaboration

EUROPE

CONSTELLA® available
in certain European countries through partnership

CHINA

Under review by
regulatory authority
for potential approval

JAPAN

LINZESS® approved in Japan through partnership